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Objectives The purpose of this study was to investigate the relationship between angiographic patterns of in-stent resteno-
sis (ISR) after femoropopliteal (FP) stenting and the frequency of refractory ISR.
Background In-stent restenosis after FP stenting is an unsolved problem. The incidence and predictors of refractory resteno-
sis remain unclear.
Methods This study was a multicenter, retrospective observational study. From September 2000 to December 2009, 133
restenotic lesions after FP artery stenting were classified by angiographic pattern: class I included focal lesions
(50 mm in length), class II included diffuse lesions (50 mm in length), and class III included totally occluded
ISR. All patients were treated by balloon angioplasty for at least 60 s. Recurrent ISR or occlusion was defined as
ISR or occlusion after target lesion revascularization. Restenosis was defined as 2.4 of the peak systolic veloc-
ity ratio by duplex scan or 50% stenosis by angiography.
Results Sixty-four percent of patients were male, 67% had diabetes mellitus, and 24% underwent hemodialysis. Class I
pattern was found in 29% of the limbs, class II in 38%, and class III in 33%. Mean follow-up period was 24  17
months. All-cause death occurred in 14 patients; bypass surgery was performed in 11 limbs, and major amputa-
tion was performed in 1 limb during the follow-up. Kaplan-Meier survival curves showed that the rate of recur-
rent ISR at 2 years was 84.8% in class III patients compared with 49.9% in class I patients (p  0.0001) and
53.3% in class II patients (p  0.0003), and the rate of recurrent occlusion at 2 years was 64.6% in class III pa-
tients compared with 15.9% in class I patients (p  0.0001) and 18.9% in class II patients (p  0.0001).
Conclusions Restenotic patterns after FP stenting are important predictors of recurrent ISR and occlusion. (J Am Coll Cardiol
2012;59:16–23) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.036Endovascular therapy for peripheral artery disease has become
a widespread technique, and has been recognized as a common
treatment (1). The patency rate of the femoropopliteal (FP)
artery has been improved through use of the self-expanding
nitinol stent (2), and the clinical outcome and patency of
nitinol stent has already been reported (3,4). Although the
favorable patency rate of the nitinol stent, as the population
with FP stenting continues to increase, occurrence of refractory
restenosis has become a serious problem. In the case of the
coronary artery, angiographic patterns of in-stent restenosis
(ISR) is prognostically important, and the risk factors of
refractory restenosis are well established (5,6).
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accepted September 5, 2011.The purposes of this study were to investigate the incidence
and predictors of refractory restenosis after FP stenting and to
determine the relationship between angiographic patterns of
ISR and the frequency of refractory restenosis.
See page 24
Methods
Research design. This was a multicenter, retrospective
observational study. From September 2000 to December
2009, a total of 738 patients (915 limbs) underwent suc-
cessful FP stenting with nitinol stents for de novo lesions.
Two types of nitinol stents were used: Luminexx (Bard,
Murray Hill, New Jersey) and S.M.A.R.T. (Cordis J&J,
Miami, Florida). Of these patients, 137 (157 limbs) under-
went successful repeat angioplasty because of ISR. We
excluded patients if they were treated with laser angioplasty,
additional stenting, or had 3 months of follow-up after
repeat angioplasty. The remaining 116 patients (133 limbs)
were enrolled in this study (Fig. 1).
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December 27, 2011/January 3, 2012:16–23 Restenotic Patterns After Femoropopliteal StentingBaseline clinical characteristics and procedural data were
collected from hospital medical records or databases. The study
protocol was approved by the hospital ethics committees, and
the study was performed in accordance with the Declaration of
Helsinki. Written informed consent was obtained from every
patient.
Classification of ISR. The ISR lesions were classified by visual
stimate on angiography (Fig. 1): class I, the focal (50 mm in
ength) ISR group, included lesions positioned at the stent
ody, the stent edge, or a combination of these sites; class II,
he diffuse (50 mm in length) ISR group, includes not
nly stent body lesions, but also stent edge lesions; and class
II is the totally occluded ISR group.
ngioplasty procedure for ISR. All patients had taken
ual-antiplatelet therapy (aspirin 100 mg/day plus clopi-
ogrel 75 mg/day or ticlopidine 200 mg/day) from 2 days
efore the procedure. Unfractionated heparin was injected
ntra-arterially before the intervention at a dose of 3,000 to
,000 IU and was added as required to maintain the active
lotting time at 200 s. The target lesion was passed with
0.035-, 0.018-, or 0.014-inch guide wire. All patients were
reated by balloon angioplasty for at least 60 s, and the
iameter and length of the balloon was determined by the
urgeon on the basis of angiography. After the procedure, all
atients were prescribed lifelong aspirin (100 mg/day), and
lopidogrel or ticlopidine was stopped on or after the day of
he procedure.
ollow-up. Clinical follow-up was performed with office
isits or telephone contacts at least every 6 months after the
rocedure. Clinical examinations, duplex ultrasonography
can of the stented vessel, and occurrence of major late
linical events (including all-cause death, surgical revascu-
arization, and leg amputation) were recorded.
Figure 1 Participant Flow Through the Trial
and ISR Classification
FP  femoropopliteal; ISR  in-stent restenosis.0efinitions. Restenosis was de-
ned as 2.4 of the peak systolic
elocity ratio by the duplex scan
7,8) or50% stenosis by angiogra-
hy. An undetectable signal in
tented segments by the duplex scan
as graded as a complete occlusion.
arly ISR was defined as ISR
ithin 6 months after stenting. Re-
urrent ISR or occlusion was de-
ned as ISR or in-stent occlusion
fter target lesion revascularization.
tent fractures were classified as mi-
or (single strut fracture), moderate
fracture of 1 strut), and severe
complete separation of stent seg-
ents) (9). Coronary artery disease (CAD) was defined as stable
ngina with documented CAD, history of percutaneous coronary
ntervention, history of coronary artery bypass graft surgery, or
revious myocardial infarction. Cerebrovascular disease (CVD)
as defined as a hospital or neurologist report with the diagnosis
f transient ischemic attack or ischemic stroke. Below-the-knee
unoff was assessed by angiography before or after the procedure.
eg amputation was defined as amputation above the ankle.
tatistical analysis. Values are expressed as mean  SD.
ontinuous variables were examined by the unpaired t test
r analysis of variance. Categorical variables were compared
y the chi-square test. Survival curves were estimated by the
aplan-Meier method and compared with the log-rank test.
ox multivariate regression analysis was used to determine
redictors for recurrent ISR. A probability value of p 0.05
was considered statistically significant.
Results
Patients and lesion characteristics. Initial clinical and an-
giographic characteristics are shown in Tables 1 and 2. Of the 133
limbs analyzed, 29% were class I (focal ISR), 38% class II (diffuse
ISR), and 33% class III (totally occluded ISR). Balloon angio-
plasty was performed in all cases. Early ISR was shown in 20% of
limbs. Presence of CVD, lesion length, and total stent length
were significantly different among the ISR classes. Compared
with stenotic ISR group (classes I and II) and class III,
presence of CVD and lesion length were significantly different.
Clinical follow-up. The mean follow-up period was 24 
17 months. The recurrent ISR rate was 49.9% in class I,
53.3% in class II, 84.8% in class III, and 52.0% in the
stenosis group at 2 years (Figs. 2 and 3); the recurrent
occlusion rate was 15.9%, 18.9%, 64.6%, and 17.6%, respec-
tively (Figs. 4 and 5). There were significant differences
between classes I and III (recurrent ISR, p  0.0001;
recurrent occlusion, p  0.0001), between classes II and III
(recurrent ISR, p  0.0003; recurrent occlusion, p 
.0001), and between the stenosis group and class III
recurrent ISR, p  0.0001; recurrent occlusion, p 
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
CVD  cerebrovascular
disease
FP  femoropopliteal
HR  hazard ratio
ISR  in-stent restenosis
RVD  reference vessel
diameter
TASC  TransAtlantic
Inter-Society Consensus.0001). All-cause death occurred in 14 patients; bypass surgery
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Restenotic Patterns After Femoropopliteal Stenting December 27, 2011/January 3, 2012:16–23was performed on 11 limbs, and major amputation was performed
on 1 limb during the follow-up. Although the difference in
survival rate was not significant among the classes, the bypass
surgery rate (Figs. 6 and 7) was significantly high for class III cases
(class I vs. class II, p  0.0077; class II vs. class III, p  0.0025;
stenosis group vs. class III, p  0.0001).
Multivariate analysis. Risk factors for recurrent ISR and
cclusion were examined using the Cox hazard model. Clini-
ally pre-specified predictors (age, sex, hypertension, hyperlip-
demia, diabetes mellitus, current smoker, hemodialysis, CAD,
VD, critical limb ischemia, statin administration, warfarin
dministration, cilostazol administration, ISR classification,
esion length, reference vessel diameter, type of nitinol stent,
tent fracture, below-the-knee run-off, early restenosis, and
ransAtlantic Inter-Society Consensus [TASC] II classifica-
Patient CharacteristicsTable 1 Patient Characteristics
Stenosis
Total
(n  89)
Class I
(n  39)
Age, yrs 72 8.4 73 8.1
Body mass index, kg/m2 21.9 2.7 22.2 3.4
Male 65 59
Hypertension 88 85
Hypercholesterolemia 36 36
Diabetes mellitus 73 69
Current smoker 24 28
Hemodialysis 27 18
CAD 64 62
CVD 35 21
CLI 24 20
Statin 49 46
Warfarin 11 10
Cilostazol 58 67
Values are mean  SD or %.
CAD  coronary artery disease; CLI  critical limb ischemia; CVD 
In-Stent Restenosis Lesion CharacteristicsTable 2 In-Stent Restenosis Lesion Characteristics
Stenosis
Total
(n  89)
Class I
(n  39)
Lesion length, mm 91.4 67.1 32.0 17.3
Reference vessel diameter, mm 5.4 0.7 5.5 0.8
Type of nitinol stent, %
Luminexx 31 31
S.M.A.R.T. 69 69
Total stent length, mm 163.5 83.1 143.6 84.5
Stent fracture* 25 21
Type of fracture, limbs,
minor/moderate/severe
7/14/1 4/4/0
Below-the-knee runoff (0–3) 1.9 0.9 2.1 0.8
Early ISR† 16 18
TASC II classification pre-stenting,
limbs, A/B/C/D
23/11/33/22 12/7/15/5
Values are mean  SD, %, or n. *Stent fracture was defined as 2 projections of stent struts int
tenting.
TASC  TransAtlantic Inter-Society Consensus.tion before stenting) with p  0.05 on Cox univariate models
were entered into the multivariable Cox regression model
(Tables 3 and 4). Multivariate analysis showed that ISR class
II (hazard ratio [HR]: 2.44; 95% confidence interval [CI]:
.33 to 4.48, p  0.004) and reference vessel diameter (HR:
.63, 95% CI: 0.44 to 0.89, p  0.008) were independent
redictors of recurrent ISR, and that ISR class III (HR: 4.06,
5% CI: 1.79 to 9.24, p  0.0008) and reference vessel
iameter (HR: 0.60, 95% CI: 0.36 to 0.99, p  0.049) were
ndependent predictors of recurrent occlusion.
iscussion
his study represents the progress after balloon angio-
lasty for FP ISR. Class III (totally occluded ISR group)
Occlusion
Class III
(n  44)
p Value
lass II
 50)
Among
3 Classes
Stenosis vs.
Occlusion
0 8.5 69 10.7 0.20 0.19
7 2.1 21.7 2.3 0.74 0.82
70 57 0.36 0.35
90 82 0.51 0.37
36 30 0.76 0.46
76 68 0.36 0.56
20 39 0.14 0.07
34 23 0.20 0.60
66 59 0.50 0.58
46 14 0.01 0.01
26 25 0.82 0.86
52 43 0.49 0.29
11 7 0.79 0.51
52 41 0.06 0.06
rovascular disease.
Occlusion
Class III
(n  44)
p Value
Class II
(n  50)
Among
3 Classes
Stenosis vs.
Occlusion
137.8 53.6 197.5 62.1 0.01 0.01
5.3 0.6 5.2 0.7 0.32 0.24
32 23 0.48 0.49
68 77 0.48 0.49
179.0 78.7 185.0 77.1 0.046 0.16
28 11 0.14 0.07
3/10/1 0/5/0 0.27 0.27
1.7 1.0 1.9 1.1 0.22 0.86
14 30 0.16 0.06
11/4/18/17 4/9/18/13 0.07 0.13
n identified x-ray film. †Early in-stent restenosis (ISR) was defined as ISR within 6 months afterC
(n
7
21.erruptio
(
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December 27, 2011/January 3, 2012:16–23 Restenotic Patterns After Femoropopliteal Stentingis associated with increased risks of recurrent ISR,
recurrent occlusion, and surgical revascularization. Un-
like the established Mehran classification for coronary
ISR (5), there is no prognostic difference between class I
focal ISR group) and class II (diffuse ISR group), even if
he cut-off point is changed from 50 mm to 30 or 80 mm.
Figure 2 Freedom From Recurrent ISR by ISR Class
There were significant differences between class I (blue line) and class III (green
ISR  in-stent restenosis.
Figure 3 Freedom From Recurrent ISR by Stenosis and Occlusi
There were significant differences between the stenosis group (red line) and the oCompared to the Mehran classification, the mean stent
length of the focal ISR group was significantly longer in
this study (143.6 mm in FP ISR, 18.3 mm in coronary
ISR). Occurrence of new restenosis in another stent
segment after angioplasty for focal ISR may participate in
the similar prognosis of these classes. Conversely, similar
p  0.0001) and between class II (red line) and class III (p  0.0003).
on group (green line) (p  0.0001). ISR  in-stent restenosis.line) (on
cclusi
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Restenotic Patterns After Femoropopliteal Stenting December 27, 2011/January 3, 2012:16–23to coronary drug-eluting stent data (10), the recurrent
ISR rate of the nonfocal ISR group (classes II and III) is
significantly high compared with that of the focal ISR
group (68.7% in nonfocal ISR group, and 49.9% in focal
ISR group at 2 years; p  0.023).
Figure 4 Freedom From Recurrent Occlusion by ISR Class
There were significant differences between class I (blue line) and class III (green
ISR  in-stent restenosis.
Figure 5 Freedom From Recurrent Occlusion by Stenosis and O
There were significant differences between the stenosis group (red line) and the oThe freedom from the recurrent restenosis rate of infrain-
guinal vein bypass grafts revised with balloon angioplasty
and open surgical techniques for stenotic lesion has been
reported to be 56.6% and 43.0% to 61.2% at 2 years, and
that from the recurrent occlusion rate to be 84.5% and
p  0.0001) and between class II (red line) and class III (p  0.0001).
ion
on group (green line) (p  0.0001). ISR  in-stent restenosis.line) (cclus
cclusi
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December 27, 2011/January 3, 2012:16–23 Restenotic Patterns After Femoropopliteal Stenting78.8% to 87.7%, respectively (11). In this study, the freedom
from recurrent ISR and occlusion rate after balloon angio-
plasty for stenotic ISR was 46.7% to 50.1% and 81.1% to
84.1% at 2 years, respectively. The results of this study show
that the progress after balloon angioplasty for stenotic ISR
of FP artery is acceptable.
Figure 6 Freedom From Bypass Surgery by ISR Class
There were significant differences between class I (blue line) and class III (green
ISR  in-stent restenosis.
Figure 7 Freedom From Bypass Surgery by Stenosis and Occlu
There were significant differences between the stenosis group (red line) and the oCompared to the stenotic ISR group (classes I and II),
the freedom from recurrent ISR and occlusion rate of class
III were remarkably low (22.7% and 42.9% at 1 year,
respectively). Balloon angioplasty for occluded ISR is unfa-
vorable, except for patients who require short-term blood
flow to heal an ischemic ulcer. In accordance with a previous
p  0.0077) and between class II (red line) and class III (p  0.0025).
on group (green line) (p  0.0001). ISR  in-stent restenosis.line) (sion
cclusi
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Restenotic Patterns After Femoropopliteal Stenting December 27, 2011/January 3, 2012:16–23report (12), the 1-year bypass patency rate after surgical
thrombectomy or transluminal balloon angioplasty for oc-
cluded polytetrafluoroethylene bypass graft was 13.5%. As
in the case of bypass graft, treatment for the occluded FP
stent and prevention of stent occlusion are major concerns.
Although directional atherectomy for ISR fails to show accept-
able long term patency (13), drug-eluting stent implantation
for ISR results in a 1-year target lesion revascularization rate of
22% (14). Furthermore, previous studies have shown good
outcomes using a paclitaxel-coated balloon (15,16), excimer
laser (17), and stent graft (18). The patency is likely to improve
in future treatments of occluded FP stent. A recent study has
reported that TASC II C and D lesions and cilostazol
administration are independent predictors of stent occlusion
after successful FP stenting (3). Early follow-up with duplex
ultrasonography for TASC II C/D lesions and cilostazol
administration may prevent stent occlusion, and consequently
reduce the surgical revascularization rate.
Among ISR classes, class II was related with the highest
presence of CVD. This finding may indicate that patients with
severe systemic arteriosclerosis are inclined to generate diffuse
ISR. In this study, stent fracture was found in 27 limbs (minor
in 7 limbs, moderate in 19 limbs, and severe in 1 limb). There
was no relationship between the incidence and morphology of
fracture and type of nitinol stent (incidence, p  0.224;
morphology, p  0.147). Although the incidence and mor-
phology of stent fracture were not statistically different among
ISR classes, the incidence of stent fracture tended to be low in
class III. Stent facture is known to be related to patency after
FP stenting (19), but the relationship with stent occlusion is
unclear. Our finding may demonstrate that stent fracture is less
related to stent occlusion compared to stent restenosis. Kaplan-
Meier survival curves showed that the freedom from recurrent
ISR was 43.0% with fracture versus 34.8% without fracture at
Univariate and Multivariate Predictors of RecurrTable 3 Univariate and Multivariate Predict
Variables
Univaria
HR (95% CI)
ISR class III 2.90 (1.83–4.56)
Lesion length (mm) 1.004 (1.002–1.007)
Reference vessel diameter (mm) 0.62 (0.44–0.87)
Early restenosis 1.92 (1.13–3.23)
*Recurrent in-stent restenosis (ISR) was defined as ISR after target l
stenting.
CI  confidence interval; HR  hazard ratio.
Univariate and Multivariate Predictors of RecurrTable 4 Univariate and Multivariate Predict
Variables
Univariate
HR (95% CI)
ISR class III 5.57 (2.88–10.77
Lesion length, mm 1.007 (1.004–1.01
Reference vessel diameter, mm 0.62 (0.39–0.99)*Recurrent occlusion was defined as in-stent occlusion after target lesion rev
Abbreviations as in Table 3.2 years (p  0.148). That class III was found in 18.5% with
fracture versus 36.8% without fracture (p  0.072) may affect
this result. Moreover, the freedom from recurrent ISR was not
significantly different for morphology of the fracture (p 
.384).
A previous study reported that TASC II C and D lesions,
emodialysis, stent fracture, and cilostazol administration
re independent predictors of primary patency (3). How-
ver, on investigation of recurrent ISR and occlusion, our
ultivariate analysis suggests that ISR type III and refer-
nce vessel diameter (RVD) are strong predictors. As RVD
as measured by visual estimation in this study, it may have
een underestimated (20). To examine the relationship
etween RVD and recurrent ISR more accurately, estima-
ion by intravascular ultrasonography is needed. In the case
f coronary artery, early restenosis is an independent pre-
ictor of repeat target lesion revascularization (6). Although
arly restenosis was omitted from our multivariate analysis,
t tends to predict recurrent ISR. In this study, early
estenosis lesions were found in only 20 limbs; that is an
mportant limitation.
tudy limitations. First, this study involved a retrospec-
ive, nonrandomized, small-sample size analysis, despite
eing a multicenter study. Second, lesion characteristics
ere not completely confident because they were mea-
ured by visual estimation. Finally, only 2 types of nitinol
are metal stents were used because these were the only
vailable stents in Japan at the time of the study.
herefore, further investigation of new-generation ni-
inol bare metal stents or drug-eluting stents is needed.
espite these limitations, the findings in this study
ndicate that restenotic pattern after FP stenting is a
trong predictor of recurrent restenosis.
SR*f Recurrent ISR*
alysis Multivariate Analysis
p Value HR (95% CI) p Value
0.01 2.44 (1.33–4.48) 0.01
0.01 1.001 (0.998–1.005) 0.50
0.01 0.63 (0.44–0.89) 0.01
0.02 1.60 (0.94–2.73) 0.09
vascularization; early ISR was defined as ISR within 6 months after
cclusion*f Recurrent Occlusion*
sis Multivariate Analysis
p Value HR (95% CI) p Value
0.01 4.06 (1.79–9.24) 0.01
0.01 1.003 (0.998–1.008) 0.23
0.046 0.60 (0.36–0.99) 0.049ent Iors o
te An
esion reent Oors o
Analy
)
1)ascularization.
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December 27, 2011/January 3, 2012:16–23 Restenotic Patterns After Femoropopliteal StentingConclusions
Restenotic patterns and RVD after FP stenting are inde-
pendent predictors of recurrent restenosis and occlusion.
Although balloon angioplasty for the stenotic ISR group is
feasible, the freedom from recurrent ISR and occlusion after
balloon angioplasty are remarkable low for totally occluded
ISR. Whereas bypass surgery is favorable treatment for
occluded ISR, the prognosis is likely to improve with future
treatments, namely, drug-eluting stent, paclitaxel-coated
balloon, excimer laser, and stent graft.
Reprint requests and correspondence: Dr. Atsushi Tosaka,
Department of Cardiology, Kokura Memorial Hospital, 1-2-3
Asano, Kokurakita-ku, Kitakyushu 802-8555, Japan. E-mail:
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